Evidence map›Paper›PMID 41935384›Full record

ReviewEuropean heart journal. Cardiovascular pharmacotherapy2026

Cardiovascular pharmacotherapy in 2025.

Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe A Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Roland Klingenberg and 8 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Innovation and constraints in cardiovascular pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Juan TamargoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, Avenida Ramón y Cajal s/n, Madrid 29040, Spain.ORCID 0000-0002-7979-7758
Stefan AgewallInstitute of Clinical Science, Oslo University, Oslo 0318, Norway.
Giuseppe AmbrosioCenter for Clinical and Translational Research-CERICLET, Department of Medicine, University of Perugia, Perugia 06156, Italy.
Claudio BorghiMedical and Surgical Sciences Deparment, University of Bologna-IRCCS AOU S. Orsola, Bologna 40138, Italy.ORCID 0000-0001-8039-8781
Elisabetta CerbaiDepartment Neurofarba, Section of Pharmacology and Toxicology, University of Florence, Firenze 50121, Italy.ORCID 0000-0001-7839-1361
Gheorghe A DanRomanian Academy of Scientists, Carol Davila University of Medicine, Bucharest 050474, Rumania.
Heinz DrexelVorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Feldkirch 6800, Austria.
Péter FerdinandyDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest 1089, Hungary.
Erik Lerkevang GroveDepartment of Cardiology, Aarhus University Hospital, Aarhus 8200, Denmark.
Roland KlingenbergDepartment of Cardiology, KerckhoffHeart and Thorax Center, Bad Nauheim 61231, Germany.
Joao MoraisciTechCare-Center for Innovative Care and Health Technology, Polytechnic University of Leiria, Leira 2414-016, Portugal.
William ParkerCardiovascular Research Unit, University of Sheffield, Sheffield S5 7AU, UK.
Bianca RoccaDepartment of Medicine and Surgery, LUM University, Casamassima, Bari 70010, Italy.
Patrick SulzgruberDepartment of Medicine, Division of Cardiology, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0001-5146-0099
Anne Grete SembPreventive Cardio-Rheuma Clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital, Oslo 0370, Norway.
Samuel SossallaMedical Clinic I, Cardiology and Angiology, Gießen & Department of Cardiology, Campus Kerckhoff, Bad Nauheim and Justus-Liebig-Universität, 35392 Gießen, Germany.
Juan Carlos KaskiMolecular and Clinical Sciences Research Institute, St.George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Dobromir DobrevInstitute of Pharmacology, Medical Faculty, University Duisburg-Essen, Essen 45122, Germany; Montréal, Quebec H1T1C8.ORCID 0000-0002-4612-117X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesAnimalsDrug ApprovalForecastingHumansTreatment OutcomeCardiovascular AgentsCardiovascular drugsCardiovascular pharmacotherapyPharmacological strategies

Identifiers

PMID41935384
PMCPMC13185746

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.